702 Efficacy and Safety of Delayed-Release Oral mesalamine At 4.8g/D (800mg Tablet) in the Treatment of Moderately Active Ulcerative Colitis: Results of the Ascend III Study

Autor:	Jaroslaw Regula, Chyon-Hwa Yeh, Njegica Jojic, Elena Belousova, Brian G. Feagan, William J. Sandborn, Milan Lukas, Piotr Krzeski, Bruce R. Yacyshyn, Stephen B. Hanauer
Rok vydání:	2008
Předmět:	medicine.medical_specialty Hepatology business.industry Internal medicine Gastroenterology Medicine Delayed release (linguistics) business medicine.disease Ulcerative colitis
Zdroj:	Gastroenterology. 134:A-99
ISSN:	0016-5085
DOI:	10.1016/s0016-5085(08)60464-3
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3d256a6f3a34f566b21bef4f6dcffd3a https://doi.org/10.1016/s0016-5085(08)60464-3 Zobrazit plný text záznamu